BioLineRx’s Strong Quarter with APHEXDA Growth
Company Announcements

BioLineRx’s Strong Quarter with APHEXDA Growth

Bioline RX Ltd Sponsored ADR (BLRX) has released an update.

BioLineRx Ltd. reports a strong second quarter in 2024 with significant progress for APHEXDA, their stem cell mobilization agent, achieving formulary placement in around 37% of top transplant centers and doubling its ordering centers. The company also announced a new clinical trial with St. Jude Children’s Research Hospital to evaluate APHEXDA’s use in gene therapy for sickle cell disease, aiming to enhance treatment availability and efficiency. Financially, BioLineRx saw a net income turnaround from the previous year’s loss, underpinned by a substantial increase in net revenue and a promising cash reserve extending into 2025.

For further insights into BLRX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskBioLineRx’s Motixafortide Shows Promise in Sickle Cell Trials
TipRanks Auto-Generated NewsdeskBioLineRx Secures Extended U.S. Patent for Motixafortide
TheFlyBioLineRx receives notification of allowance from USPTO for motixafortide
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App